@Article{Nowicki2020,
journal="Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii",
issn="1642-395X",
volume="37",
number="5",
year="2020",
title="Biological drugs in the treatment of atopic dermatitis –
current recommendations of the Polish Dermatological
Society, the Polish Society of Allergology, the Polish Pediatric
Society and the Polish Society of Family Medicine",
abstract="Atopic dermatitis (AD) is secondary to genetic, immunological and microbiological disorders as well as epidermal barrier defects, which are the main targets of therapy. The disease proceeds with periodic exacerbations. Its development and course are influenced by numerous environmental and individual factors. In recent decades, in industrialized countries, there has been a threefold increase in the incidence of AD. There is also an increasing number of cases resistant to topical treatment. Effective treatment of AD should provide control of clinical symptoms, prevent exacerbations and improve the quality of life of patients. The multifactorial etiopathogenesis and various endotypes and phenotypes of AD justify the tendency to optimize and personalize the therapy. Currently, we recommend the use of dupilumab for the treatment of patients from 12 years of age with moderate and severe atopic dermatitis, who do not respond to topical treatment.",
author="Nowicki, Roman
and Trzeciak, Magdalena
and Rudnicka, Lidia
and Szepietowski, Jacek
and Kulus, Marek
and Kupczyk, Maciej
and Mastalerz-Migas, Agnieszka
and Peregud-Pogorzelski, Jarosław
and Jahnz-Różyk, Karina
and Narbutt, Joanna
and Czarnecka-Operacz, Magdalena
and Czajkowski, Rafał
and Grubska-Suchanek, Elżbieta
and Krasowska, Dorota
and Kręcisz, Beata
and Kowalewski, Cezary
and Lesiak, Aleksandra
and Olszewska, Malgorzata
and Samochocki, Zbigniew
and Śpiewak, Radosław
and Wilkowska, Aleksandra",
pages="617--624",
doi="10.5114/ada.2020.100496",
url="http://dx.doi.org/10.5114/ada.2020.100496"
}